Galectin-3, Neuroinflammation, and Mental Health: Exploring the Neuroimmune Axis in Mood, Stress, and Brain Disorders
Share
A growing body of published research and clinical practice is reframing mental health conditions by applying an immuno-inflammatory perspective. Within this fast-growing body of research, galectin-3 (Gal-3) is emerging as a key upstream regulator. While traditionally studied in fibrosis, cancer, and cardiometabolic disease, Gal-3 is increasingly implicated in neuroinflammation, synaptic dysfunction, and mood disorders—making it a compelling target in integrative psychiatry and other areas related to brain, mood, and neurological function.
Galectin-3: Key Neuroimmune Amplifier
Galectin-3 is expressed by activated microglia and astrocytes, where it functions as a pattern-recognition and signaling molecule. It plays a central role in amplifying inflammatory cascades through:
- NF-κB activation increasing pro-inflammatory cytokines (IL-6, TNF-α)
- STAT3 signaling which sustains glial activation
- NLRP3 inflammasome priming driving neuroinflammation
- Microglial phenotype shifts (M1-like activation)
Recent research points to Gal-3 as an upstream alarmin that is directly involved in major depressive disorder (MDD) pathophysiology, with significant effects on:
- Neuroinflammation
- Synaptic plasticity and neurogenesis
- Neuroendocrine stress signaling
These findings position Gal-3 as an active, culprit biomarker driving neuropsychiatric disease processes (1).
Sleep, Mood, and Cognitive Disorders: The Perfect Storm
Additional 2025 research expands this framework into sleep regulation and affective disorders, reinforcing that inflammatory mediators—including galectin-3 pathways—may disrupt:
- Sleep architecture and circadian signaling
- Neurotransmitter balance
- Stress-response systems (HPA axis)
Given the direct, bidirectional relationship between sleep disturbance and depression, Gal-3 is increasingly shown to be a key upstream mediator that, when elevated, can drive multiple pathogenic processes related to stress responses and neurological function (2).
Similarly, emerging psychiatric research in bipolar disorder demonstrates that Gal-3 correlates to affective symptom severity and frequency of episodes (3).
Pectin Compounds in Neuroinflammation and Depression Models
Preclinical studies using citrus pectin demonstrates:
- Reduced depression-like behaviors in post-ischemic models
- Downregulation of NF-κB p65 and phosphorylated STAT3 (pSTAT3)
- Attenuation of neuroinflammatory signaling cascades
These findings are notable because they directly intersect with Gal-3–regulated pathways, suggesting a mechanistic bridge between dietary polysaccharides and neuroimmune modulation (4).
Modified Citrus Pectin (MCP): Galectin-3 Inhibitor with Neurological Benefits
Modified citrus pectin is structurally modified to low molecular weight which allows it to absorb into the circulation and bind the carbohydrate recognition domain of Gal-3.
Across experimental and translational studies, MCP has been shown to:
- Bind and inhibit circulating Gal-3
- Reduce fibrotic and inflammatory signaling
- Modulate immune activation and cytokine expression
- Reduce neuroinflammatory activity
A growing body of research supports MCP’s primary role as a functional Gal-3 antagonist, with implications extending into CNS-related conditions (5).
Additionally, recent cellular and molecular research continues to map galectin-mediated signaling networks, reinforcing the therapeutic potential of targeting Gal-3 with MCP in inflammatory diseases—including those affecting cognitive function (6).
Clinical Implications for Integrative Mental Health
While research is still in the early stages, breakthrough clinical and preclinical data demonstrates the role of elevated Gal-3 in neuroinflammation and neurodegeneration, as well as in cognitive impairment, mood, and sleep disorders. Specific findings show:
- Gal-3 serves as a cross-system biomarker linking metabolic, immune, and psychiatric dysfunction
- Targeting Gal-3 offers a strategy to address upstream drivers of neuroinflammation
- MCP and related compounds may provide adjunctive support in treatment-resistant depression, cognitive dysfunction, and neuroinflammatory states
Targeting Gal-3 offers an important upstream strategy for the modulation of inflammatory signaling networks, with clear benefits in areas of brain health, immune function, and balance of inflammatory signaling.
Galectin-3 sits at a critical intersection of immune activation, neuroinflammation, and brain function. As research advances, targeting Gal-3—particularly through compounds like modified citrus pectin—may become an important component of precision, inflammation-informed mental health care.
References
1. Peixoto LC, da Rosa MM. New perspectives on galectin in major depressive disorder treatment. Biochem Pharmacol. 2025 Mar;233:116786. doi: 10.1016/j.bcp.2025.116786. Epub 2025 Jan 31. PMID: 39892331.
2. Zhou W. Plasma Galectin-3 as a potential predictor of chronic insomnia and its association with NLRP3 inflammasome activation in chronic migraine: A case-control study. Sleep Med. 2025 Dec;136:106793. doi: 10.1016/j.sleep.2025.106793. Epub 2025 Sep 1. PMID: 40907401.
3. Ozkaya AL, Gürbüzer N, Tozoğlu EÖ, Akyildirim S, Mercantepe F. Serum Galectin-3 and IL-6 as Inflammatory Markers in Bipolar Disorder: Insights from Manic and Euthymic Episodes. J Clin Med. 2025 Jan 26;14(3):803. doi: 10.3390/jcm14030803. PMID: 39941474; PMCID: PMC11818607.
4. Ai, Zhibing & Liu, Yong & Shi, Xueyu & Hu, Wei & Zhang, Yueliang & An, Ran & Lei, Gongwun. (2023). The Protective Effects of Apple Pectin and Citrus Pectins on Post-Cerebral I/R Depression in Mice: The Role of NF-κB-p65 and pSTAT3 pathways. Arabian Journal of Chemistry. 16. 104864. 10.1016/j.arabjc.2023.104864.
5. Cui Y, Zhang NN, Wang D, Meng WH, Chen HS. Modified Citrus Pectin Alleviates Cerebral Ischemia/Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation via TLR4/NF-ĸB Signaling Pathway in Microglia. J Inflamm Res. 2022 Jun 9;15:3369-3385. doi: 10.2147/JIR.S366927. PMID: 35706530; PMCID: PMC9191615.
6. Akgöl J, Kutlay Ö, Keskin Aktan A, Fırat F. Assessment of Modified Citrus Pectin's Effects on Dementia in the Scopolamine-Induced Alzheimer's Model in Adult Male Wistar Rats. Curr Issues Mol Biol. 2024 Dec 11;46(12):13922-13936. doi: 10.3390/cimb46120832. PMID: 39727960; PMCID: PMC11727308.